Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples